Glox Therapeutics secures £4.3m seed funding to combat AMR
16th November 2023 Uncategorised 0The bacteriocin development programme will first target pseudomonas aeruginosa
More: Glox Therapeutics secures £4.3m seed funding to combat AMR
Source: News